STOCK TITAN

OrthoPediatrics Corp. Expands Trauma and Deformity Portfolio with 3P™ Pediatric Plating Platform™ Hip System

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Very Positive)
Tags

OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.

The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.

Loading...
Loading translation...

Positive

  • Received 5th FDA approval in 2025, demonstrating strong regulatory momentum
  • Expanding product portfolio with innovative trauma and deformity treatment solutions
  • Strategic rollout planned with multiple system launches through 2026
  • Potential for increased market share in pediatric orthopedic plating segment

Negative

  • None.

News Market Reaction 1 Alert

+4.06% News Effect

On the day this news was published, KIDS gained 4.06%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WARSAW, Ind., May 07, 2025 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced the expansion of its Trauma and Deformity portfolio with 3P™ Pediatric Plating Platform™ Hip System, the first of several systems in the 3P family. This represents the company’s 5th FDA approval in 2025.

3P Pediatric Plating Platform Hip System is a new plate and screw platform to modernize and revolutionize trauma and deformity correction treatment in the lower extremities. This family of plating systems will provide surgeons unparalleled coverage for a variety of Trauma and Deformity correcting indications by delivering unique implants and instruments to improve surgical workflow and inventory efficiency.  The beta launch for 3P Hip is expected to be followed by the next system, 3P Small/Mini, early in 2026, followed by expected launches of additional systems in the upcoming years. Once complete the result we be the complete transformation of the Company’s plate and screw product portfolio, giving OrthoPediatrics the most robust and modern plating portfolio in pediatric orthopedic history.

OrthoPediatrics Trauma and Deformity division President, Joe Hauser commented “The 3P Pediatric Plating Platform is a world-class system with significant opportunity to fill unmet needs. This family of systems is one of the largest product endeavors that we've taken on within the Trauma and Deformity side in our company history, and we are excited for 3P Hip to be the first step to further share-taking opportunities within the plating franchise.”

CEO, David Bailey echoed those comments, saying “We continue to focus on providing surgeons with a comprehensive portfolio of innovative orthopedic treatments to address all unmet needs for pediatric patients, and the latest FDA approval for the 3P Hip System marks our 5th FDA approval thus far in 2025. I’m incredibly proud of the work our R&D team has done to achieve this goal and look forward to the addition of many more products in the future as we continue to expand our portfolio.”

About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets over 80 products that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.

Investor Contact
Philip Trip Taylor
Gilmartin Group
philip@gilmartinir.com
415-937-5406


FAQ

What is OrthoPediatrics' new 3P Pediatric Plating Platform Hip System?

The 3P Pediatric Plating Platform Hip System is a new plate and screw platform designed to modernize trauma and deformity correction treatment in lower extremities, representing OrthoPediatrics' 5th FDA approval in 2025.

When will KIDS stock launch the 3P Small/Mini system?

OrthoPediatrics plans to launch the 3P Small/Mini system in early 2026, following the beta launch of the 3P Hip system.

How many FDA approvals has OrthoPediatrics (KIDS) received in 2025?

OrthoPediatrics has received 5 FDA approvals in 2025, with the 3P Pediatric Plating Platform Hip System being the latest approval.

What is the significance of the 3P platform for OrthoPediatrics (KIDS)?

The 3P platform represents one of OrthoPediatrics' largest product initiatives in their Trauma and Deformity division, aiming to create the most comprehensive modern plating portfolio in pediatric orthopedic history.
Orthopedia

NASDAQ:KIDS

KIDS Rankings

KIDS Latest News

KIDS Latest SEC Filings

KIDS Stock Data

445.37M
16.87M
32.71%
71.29%
4.85%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
WARSAW